Fundraising September 15, 2024 – October 1, 2024 About fundraising

Upfront FOLFOXIRI plus bevacizumab and reintroduction after...

  • Main
  • 2020 / 3
  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after...

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Cremolini, Chiara, Antoniotti, Carlotta, Rossini, Daniele, Lonardi, Sara, Loupakis, Fotios, Pietrantonio, Filippo, Bordonaro, Roberto, Latiano, Tiziana Pia, Tamburini, Emiliano, Santini, Daniele, Pass
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(19)30862-9
Date:
March, 2020
File:
PDF, 416 KB
2020
Conversion to is in progress
Conversion to is failed